Tolvaptan-d7

• Description :

  Tolvaptan-d7 is the deuterium labeled Tolvaptan. Tolvaptan is a selective, competitive arginine vasopressin receptor 2 antagonist with an IC50 of 1.28μM for the inhibition of AVP-induced platelet aggregation[1][2].

• UNSPSC :

  12352005

• Target :

  Autophagy; Isotope-Labeled Compounds; Vasopressin Receptor

• Type :

  Isotope-Labeled Compounds

• Related Pathways :

  Autophagy; GPCR/G Protein; Others

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Cardiovascular Disease; Endocrinology; Cancer

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(C1=C(C=C(C=C1)NC(C2=C(C([2H])=C([2H])C([2H])=C2[2H])C([2H])([2H])[2H])=O)C)N3C4=CC=C(Cl)C=C4C(CCC3)O

• Molecular Formula :

  C26H18D7ClN2O3

• Molecular Weight :

  455.98

• References & Citations :

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Friedman B, Cirulli J. Hyponatremia in critical care patients: Frequency, outcome, characteristics, and treatment with the vasopressin V (2) -receptor antagonist tolvaptan. J Crit Care. 2012 Aug 8.|[3]Inomata T. Tolvaptan (vasopressin receptor antagonist) .Nihon Rinsho. 2011 Nov;69 Suppl 9:408-11.|[4]Vaduganathan M, Gheorghiade M, Pang PS, Konstam MA, Zannad F, Swedberg K, Grinfeld L, Burnett JC Jr, Krasa HB, Zimmer C, Blair J, Ouyang J, Maggioni AP; EVEREST investigators. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. J Cardiovasc Med (Hagerstown) . 2012 Jul;13 (7) :415-22.|[5]Y Yamamura et al. OPC-41061, a Highly Potent Human Vasopressin V2-Receptor Antagonist: Pharmacological Profile and Aquaretic Effect by Single and Multiple Oral Dosing in Rats. J. Pharmacol. Exp. Ther. 1998, 287 (3), 860-867.|[6]RW Schrier et al. Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist, for Hyponatremia. N Engl J Med 2006, 355, 2099-2112.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Isotope-Labeled Compounds

• Clinical Information :

  No Development Reported

• Isoform :

  V2 Receptor

• CAS Number :

  [1246818-18-7]